---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-055264"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:34:08.981198+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma Q1 2026 net loss $6.1M; cash $25.1M; NXP900 Phase 1b data expected summer

## Summary
- Cash and equivalents $25.1M as of March 31, 2026, down from $31.6M at Dec 31, 2025.
- Net loss $6.1M for Q1 2026 vs $5.3M in Q1 2025, increase driven by R&D and G&A costs.
- R&D expenses $4.1M, up $0.4M YoY; G&A $2.2M, up $0.3M YoY.
- NXP900 Phase 1b clinical program enrolling patients in US; monotherapy and combination arms ongoing.
- Preliminary Phase 1b data readout for NXP900 expected in summer 2026.

## SEC filing metadata
- accession: 0001104659-26-055264
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465926055264/0001104659-26-055264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465926055264/tm2613389d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-055264
- JSON: https://secwatch.observer/filing/0001104659-26-055264.json
- Plain text: https://secwatch.observer/filing/0001104659-26-055264.txt

## Key facts
- Earnings Releases
  Nuvectis Pharma, Inc. reported financial results for the first quarter ended March 31, 2026.
  - Period: the first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 5, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465926055264/0001104659-26-055264-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.